How to buy Agios Pharm stock (AGIO)

Agios Pharm is a biotechnology business based in the US. Agios Pharm shares (AGIO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $35.35 – a decrease of 17.19% over the previous week. Agios Pharm employs 383 staff and has a trailing 12-month revenue of around $32.9 million.

Our top picks for where to buy Agios Pharm stock

Buy Agios Pharm stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Agios Pharm stock price (NASDAQ: AGIO)

Use our graph to track the performance of AGIO stocks over time.

Agios Pharm shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$35.35
52-week range	$20.96 - $62.58
50-day moving average more info button	$49.73
200-day moving average more info button	$42.08
Wall St. target price	$56.50
PE ratio more info button	3.3465
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$11.66

Is it a good time to buy Agios Pharm stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Agios Pharm price performance over time

Historical closes compared with the close of $35.42 from 2024-12-20

1 week (2024-12-13)	-9.10%
1 month (2024-11-22)	-36.39%
3 months (2024-09-20)	-23.91%
6 months (2024-06-21)	-21.67%

1 year (2023-12-22)	47.95%
2 years (2022-12-23)	31.04%
3 years (2021-12-23)	35.83
5 years (2019-12-23)	49.67

Is Agios Pharm stock undervalued or overvalued?

Valuing Agios Pharm stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Agios Pharm's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Agios Pharm's P/E ratio

Agios Pharm's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Agios Pharm shares trade at around 3x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Agios Pharm financials

Revenue TTM	$32.9 million
Gross profit TTM	$12.5 million
Return on assets TTM	-18.18%
Return on equity TTM	53.66%
Profit margin	2051.38%
Book value	$28.53
Market Capitalization more info button	$2.2 billion

TTM: trailing 12 months

Agios Pharm share dividends

We're not expecting Agios Pharm to pay a dividend over the next 12 months.

Agios Pharm share price volatility

Over the last 12 months, Agios Pharm's shares have ranged in value from as little as $20.96 up to $62.58. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agios Pharm's is 0.751. This would suggest that Agios Pharm's shares are less volatile than average (for this exchange).

Agios Pharm overview

Agios Pharmaceuticals, Inc. , a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

null
What percentage of Agios Pharm is owned by insiders or institutions?
Currently 1.509% of Agios Pharm shares are held by insiders and 107.716% by institutions. How many people work for Agios Pharm?
Latest data suggests 383 work at Agios Pharm. When does the fiscal year end for Agios Pharm?
Agios Pharm's fiscal year ends in December. Where is Agios Pharm based?
Agios Pharm's address is: 88 Sidney Street, Cambridge, MA, United States, 02139 What is Agios Pharm's ISIN number?
Agios Pharm's international securities identification number is: US00847X1046 What is Agios Pharm's CUSIP number?
Agios Pharm's Committee on Uniform Securities Identification Procedures number is: 00847X104